Cargando…
Is There a Role for Dose Modification of TKI Therapy in CML?
PURPOSE OF REVIEW: For patients with chronic phase chronic myeloid leukemia (CP-CML), there is an increasing focus on personalization of therapy with dose modifications of tyrosine kinase inhibitors (TKIs) to reduce side effects and maintain efficacy. Dose reductions are also being considered in cli...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647386/ https://www.ncbi.nlm.nih.gov/pubmed/31197525 http://dx.doi.org/10.1007/s11899-019-00524-w |